Atorvastatin correlates with decreased risk of esophageal cancer: A population-based casecontrol study from Taiwan

Objectives: The aim of this study was to explore the association between the use of statins and esophageal cancer in Taiwan.Methods: We designed a casecontrol study using database from the Taiwan National Health Insurance program. In all, 549 patients (cases) aged 20 years or older diagnosed recently with esophageal cancer, from 2000 to 2009, and 2,196 subjects (controls) without esophageal cancer participated in this study. The association between esophageal cancer and the use of statins and other co-morbidities was measured.Results: After adjustment for covariates, multivariate logistic regression showed that patients with a cumulative duration of ]12 months of using atorvastatin might have a reduced risk of esophageal cancer, compared with those who did not use statins (odds ratio [OR] 0.14, 95% confidence interval [CI] 0.040.56). The other statins could not show a significant association with esophageal cancer. Age (OR 1.01, 95% CI 1.001.01), alcoholism (OR 3.83, 95% CI 3.014.89), and esophageal diseases (OR 4.60, 95% CI 3.466.12) were independent factors significantly associated with esophageal cancer.Conclusions: Use of atorvastatin ]12 months may correlate with an 86% reduction of esophageal cancer risk.Keywords: atorvastatin; esophageal cancer; stati

Atorvastatin correlates with decreased risk of esophageal cancer: A population-based casecontrol study from Taiwan

Objectives: The aim of this study was to explore the association between the use of statins and esophageal cancer in Taiwan.Methods: We designed a casecontrol study using database from the Taiwan National Health Insurance program. In all, 549 patients (cases) aged 20 years or older diagnosed recently with esophageal cancer, from 2000 to 2009, and 2,196 subjects (controls) without esophageal cancer participated in this study. The association between esophageal cancer and the use of statins and other co-morbidities was measured.Results: After adjustment for covariates, multivariate logistic regression showed that patients with a cumulative duration of ]12 months of using atorvastatin might have a reduced risk of esophageal cancer, compared with those who did not use statins (odds ratio [OR] 0.14, 95% confidence interval [CI] 0.040.56). The other statins could not show a significant association with esophageal cancer. Age (OR 1.01, 95% CI 1.001.01), alcoholism (OR 3.83, 95% CI 3.014.89), and esophageal diseases (OR 4.60, 95% CI 3.466.12) were independent factors significantly associated with esophageal cancer.Conclusions: Use of atorvastatin ]12 months may correlate with an 86% reduction of esophageal cancer risk.Keywords: atorvastatin; esophageal cancer; stati

Paediatric head CT scan and subsequent risk of malignancy and benign brain tumour: a nation-wide population-based cohort study

BACKGROUND: To evaluate the possible association between paediatric head computed tomography (CT) examination and increased subsequent risk of malignancy and benign brain tumour. METHODS: In the exposed cohort, 24 418 participants under 18 years of age, who underwent head CT examination between 1998 and 2006, were identified from the Taiwan National Health Insurance Research Database (NHIRD). Patients were followed up until a diagnosis of malignant disease or benign brain tumour, withdrawal from the National Health Insurance (NHI) system, or at the end of 2008. RESULTS: The overall risk was not significantly different in the two cohorts (incidence rate=36.72 per 100 000 person-years in the exposed cohort, 28.48 per 100 000 person-years in the unexposed cohort, hazard ratio (HR)=1.29, 95% confidence interval (CI)=0.90–1.85). The risk of benign brain tumour was significantly higher in the exposed cohort than in the unexposed cohort (HR=2.97, 95% CI=1.49–5.93). The frequency of CT examination showed strong correlation with the subsequent overall risk of malignancy and benign brain tumour. CONCLUSIONS: We found that paediatric head CT examination was associated with an increased incidence of benign brain tumour. A large-scale study with longer follow-up is necessary to confirm this result